LumiraDx Presents Its Next-Generation POC Diagnostics Platform and Fast Lab Solutions at MEDLAB Middle East

By Carolyn Moody, RN - News Editor
Posted on 25 Jan 2022

Image: LumiraDx at MEDLAB Middle East (Photo courtesy of LumiraDx)

LumiraDx (London, UK) presented its next-generation point of care diagnostics platform which provides a broad menu of lab comparable results on a single, portable diagnostic platform at MEDLAB Middle East 2022. LumiraDx also highlighted its Fast Lab Solutions which enable laboratories to improve throughput by using current molecular infrastructure and eliminating the need for extraction and purification.

The 21st MedLab Middle East took place in Dubai and was once again be co-located with Arab Health, bringing together an international audience of almost 4,000 exhibitors from the healthcare and laboratory industries from nearly 160 countries and more than 60,000 attendees across the four days. MedLab Middle East showcases the future of medical technology to the healthcare and laboratory communities. This year’s event allowed delegates to network with industry peers, meet, explore the latest products and attend educational sessions. Alongside the exhibition, MedLab Middle East runs the region's only multi-disciplinary congress with eight CME accredited tracks covering topics such as Laboratory management and molecular diagnostics.

LumiraDx exhibited for the first time in-person at MedLab Middle East where its team demonstrated its transformative tests and technology alongside its Fast Lab Solutions. LumiraDx demonstrated its transformational point of care solution, the innovative LumiraDx Platform which is designed to perform a broad menu of tests, including infectious disease, cardiovascular disease, diabetes, and coagulation disorders and deliver lab-comparable performance with results in less than 12 minutes. The next generation point of care diagnostic system combines a small, portable instrument; microfluidic test strip; simple, standardized workflow; and seamless, secure digital connectivity to the Cloud and hospital IT systems. It is designed to be affordable and accessible for healthcare providers globally, and to strengthen community-based healthcare.

LumiraDx also highlighted its COVID-19 testing solutions for use on the LumiraDx Platform, including its LumiraDx SARS-CoV-2 Ag Test, LumiraDx SARS-CoV-2 Ag Pool Test and LumiraDx SARS-CoV-2 Ab Test. The company also presented Fast Lab Solutions, a dedicated LumiraDx business unit that supports high-complexity laboratory testing by utilizing its innovative qSTAR (Selective Temperature Amplification Reaction) nucleic acid amplification technology in an accessible high-throughput format to leverage current molecular laboratory operations. qSTAR is transforming molecular diagnostics by providing fast, accurate, and high throughput testing solutions with rapid amplification within 20 minutes or less on open RT-PCR instrumentation. Utilizing FastLab Solutions enables laboratories to improve efficiency and reduce time to result.

Related Links:
LumiraDx

Visit expo >

Gold Member

Clinical Chemistry Assay

Sorbitol Dehydrogenase (SDH)

Online QC Software
Acusera 24•7

Electrolyte Analyzer

CBS-4000 (CBS-400)

Chromogenic Culture System

InTray™ COLOREX™ ECC

Latest Medlab 2022 News

Channels

Clinical Chemistry

view channel

Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia

Primary ciliary dyskinesia is a rare lung disease that affects about one in 7,500 to 10,000 live births worldwide. Symptoms can begin in the newborn period and progress to recurrent respiratory infections... Read more

Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Image: Three gray matter (GM) structural networks related to default mode network (DMN). Three GM structural networks related to DMN that were identified are shown. (A) anterior DMN; (B) posterior DMN-I, including the posterior cingulate cortex (PCC) and precuneus; and (C) posterior DMN-II, including the PCC, precuneus, inferior parietal cortex, and lateral temporal cortices. (Photo courtesy of Nagaya et al., 2026, PLOS One, CC-BY 4.0)

Plasma Vitamin C Levels Associated with Brain Structure and Connectivity in Aging

Previous studies have linked vitamin C–rich diets with lower risk of cognitive impairment in older adults. However, few investigations have directly examined blood plasma vitamin C in relation to brain... Read more

Mass Spectrometry Detects Tumor Metabolites for Cancer Monitoring

Cancer’s altered metabolism complicates how clinicians detect and monitor tumors, because nutrient use can shift with context and time. Measuring small-molecule metabolites that distinguish malignant from... Read more

Molecular Diagnostics

view channel

Image: Professor Alexander Hoischen using long read genome sequencing (Photo courtesy of Radboudumc)

Long-Read DNA Test Improves Diagnosis of Rare Genetic Diseases

Rare diseases affect up to 400 million people worldwide, yet many remain difficult to diagnose and often require years-long diagnostic journeys. Approximately 80% have a genetic basis, but conventional... Read more

At-Home Urine Collection Kit Enables High-Throughput STI Screening

Sexually transmitted infection screening often hinges on access to private, convenient sample collection and timely laboratory processing. Many patients face logistical or privacy barriers that limit participation... Read more

Noninvasive Sequencing Test Approaches Invasive Genome Sequencing for Prenatal Screening

Prenatal genetic evaluation guides obstetric care, but standard diagnostics often require invasive procedures that carry risks, stress, and access barriers. Noninvasive prenatal testing (NIPT) has expanded... Read more

Blood-Based Assay Detects HER2 Mutations to Guide NSCLC Treatment

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, and a subset of patients harbor HER2 (ERBB2) mutations that may be addressed with precision therapies. These HER2‑mutant tumors... Read more

Hematology

view channel

Immunology

view channel

Image: The study evaluated SARS-CoV-2 antibody profiling, specifically titers against the spike (S) and nucleocapsid (N) proteins, as a tool to characterize long COVID (Image credit: iStock)

Antibody Profiles Provide Clues to Long COVID Severity and Symptoms

Persistent symptoms after acute COVID-19 affect millions of people, causing fatigue, respiratory issues, and cognitive deficits that can be difficult to quantify with standard tests. Clinical teams lack... Read more

Aptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection

Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more

Study Points to Autoimmune Pathway Behind Long COVID Symptoms

Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more

Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response

Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more

Microbiology

view channel

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

New Protein Targets Support Diagnostics for Louse-Borne Relapsing Fever

Louse-borne relapsing fever is a neglected infection caused by Borrelia recurrentis and spread by body lice, with untreated mortality reaching up to 20%. Recurrent febrile episodes complicate recognition... Read more

TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy

Congenital TORCH infections can be asymptomatic during pregnancy yet cause stillbirth, birth defects, and lifelong disability in infants. Many regions still lack robust surveillance to guide testing and... Read more

New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs

Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more

Pathology

view channel

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer

Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more

$Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)$

See LabMedica in...

LabMedica

LumiraDx Presents Its Next-Generation POC Diagnostics Platform and Fast Lab Solutions at MEDLAB Middle East

Latest Medlab 2022 News

Channels